2028 Clinical Development Research Trials 
Drug Discovery World
DECEMBER 7, 2022
Data analytics company Phesi analysed 2,358 clinical trials involving collagen. In the first 10 months of 2022, there were more than 225 new trials, compared with 125 in 2012. billion by 2028. Phesi’s analysis shows that just 27% of trials received industry funding. billion USD, and is expected to grow to $16.7
The Premier Consulting Blog
NOVEMBER 20, 2023
Food and Drug Administration (FDA) made public a potentially game-changing proposal concerning the regulatory framework for laboratory-developed tests (LDTs). Understanding the nuances and implications of these changes is paramount for specialists in regulatory affairs and the clinical development arena. billion each year.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 8, 2020
Investment in Research & Development remained at c. Almirall will initiate a Phase III trial soon to demonstrate the drug’s efficacy and safety in China. If the company chooses to exercise the option, Almirall plans to start a Phase III trial in CTCL in 2021 to secure launch as early as 2023.
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Limited blinded tolerability data from the ongoing Phase 3 trial, confirming the mostly mild to moderate tolerability profile as was observed in Phase 1. Protease Inhibitor Program.
The Pharma Data
JANUARY 25, 2021
Prior to November 1, 2028, the notes will be convertible only upon satisfaction of certain conditions and during certain periods. The notes will bear interest at a rate of 2.25% per year, payable semi-annually in arrears on February 1 and August 1 of each year, beginning August 1, 2021.
Expert insights. Personalized for you.
130 
Let's personalize your content